Corbion: full year 2023 results

Udgivet den 01-03-2024  |  kl. 06:00  |  

Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through application of science, today publishes its results for the year ending 31 December 2023.

Key highlights annual results 2023:

Sales € 1,443.8 million; an organic increase of 1.2%Adjusted EBITDA € 191.8 million; an organic increase of 10.3%Operating profit € 117.2 million; an organic increase of 20.8%Organic growth core activities: Sales 3.0% & Adjusted EBITDA 16.2%Q4 2023: Sales € 352.8 million and Adjusted EBITDA € 49.0 millionOrganic growth core activities: Sales -0.5% & Adjusted EBITDA 29.3% Free Cash Flow full year € 18.6 millionCovenant net debt/covenant EBITDA improved to 3.1x at year-endProposed regular cash dividend of € 0.61 per share, an increase of 9% versus prior year reflecting the positive free cash flow momentumWorld leading lactic acid plant in Thailand mechanical completed in December 2023 according to scheduleDivestment of Emulsifiers announced, completion anticipated in Q2 2024

€ million YTD 2023 YTD 2022 Total growth Organic growth
Sales 1,443.8 1,457.9 -1.0% 1.2%
Adjusted EBITDA 191.8 184.4 4.0% 10.3%
Adjusted EBITDA margin 13.3% 12.6%    
Operating profit 117.2 110.8 5.8% 20.8%
         
Core activities        
Sales 1,264.0 1,254.4 0.8% 3.0%
Adjusted EBITDA 163.7 150.1 9.1% 16.2%
Adjusted EBITDA margin 13.0% 12.0%    

Commenting on today's results, Olivier Rigaud, CEO, stated:

"I am pleased to report a 2023 full year outcome in line with what we indicated earlier. We have reported organic sales growth and double-digit organic growth in Adjusted EBITDA and Operating Profit, whilst facing a challenging geopolitical and macro-economic environment. We delivered a higher than anticipated positive free cash flow for the year due to our focus on operational efficiencies, optimizing working capital and capex discipline. As a result, we propose to increase the regular cash dividend to our shareholders with 9% to € 0.61 per share.

In Sustainable Food Solutions, sales growth was driven by pricing. We observed strong growth in our product/market adjacencies like dairy stabilizers, natural anti-oxidants and natural mold inhibitors. In Q4, we saw a continuation of the upward momentum in volume/mix growth reflecting the end of destocking.

In Lactic Acid & Specialties, we experienced lower lactic acid supply to the TotalEnergies Corbion joint venture as well as an ongoing market slowdown in semiconductors and agrochemicals. Biomedical polymers continued its double digit growth trajectory.

Algae Ingredients continued their growth momentum as a sustainable alternative to fish oil in the aquaculture industry, and concurrently we expanded our product portfolio and pipeline of high-margin products for the petfood and human nutrition segments. In 2023, the sales has grown over 50%, surpassing the € 100 million landmark.

We achieved the mechanical completion of our world leading lactic acid plant in December and are on track to commence the start-up phase after commissioning is completed near the end of the first quarter of 2024. In January 2024, we announced that we had entered into a binding agreement for the divestment of the Emulsifier business allowing Corbion to sharpen its focus on fermentation based technologies".


Attachment

20240301 Press release 4Q23_FINAL

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

09:39 DFDS-topchef: Finansiel præstation i Ekol-handel blandt årsagerne til aflyst køb
09:25 Aktier/åbning: Lidt højere marked med flotte plusser til GN, Novonesis og Genmab
09:14 Novonesis overrasker med oppræcisering i stærkt tredje kvartal
09:08 Ambus kursmål skåret til 130 kr. efter regnskab hos Redburn
09:06 Obligationer/åbning: Stort set uændret rente på dag med rentemøder
09:02 DFDS' Torben Carlsen ser først økonomisk afmatning i Europa vende i 2025
08:58 Torm fortsætter vækst og betaler udbytte - men lavere fragtpriser giver nedjustering
08:45 Vestas får sænket anbefaling af Bank of America efter Trump-sejr og regnskab
08:31 GN-topchef: Vi når formentlig ikke vending til positivt marked i Enterprise i år
08:31 Aktier/tendens: Ny stime af regnskaber - opjustering fra Novonesis, Genmab, men GN sænker
08:23 Gubra vender driftsindtjeningen til plus i tredje kvartal drevet af fedme
07:49 DFDS' fragtmængder og passagerantal hjulpet af rutetilgang
07:45 Korr: Obligationer/tendens: Udsigt til uændret åbning på dag med rentemøder
07:37 Genmabs lukning i USA indikerer positiv åbning
07:35 Zealand Pharma OVERBLIK Q3: Opmuntrende pipeline overskygger underskud
07:27 Obligationer/tendens: Udsigt til uændret åbning på dag med rentemøder
07:07 Genmabs kursmål sættes ned af amerikanske TD Cowen efter regnskab
07:05 Ørsteds kursmål sænkes hos HSBC efter regnskab og Trump-sejr
06:49 Pandora får løftet kursmålet hos JPMorgan efter regnskab
06:46 Råvarer: Oliepris dykker let på udsigt til Trump i Det Hvide Hus